Insurity Recognized as a Leader in Everest Group's PEAK Matrix® for AI-Enabled Claims Management Systems for P&C Insurance
Article content
Article content
HARTFORD, Conn. — Insurity, a leading provider of cloud-based software for property and casualty (P&C) insurers, brokers, and MGAs, today announced that it has been recognized as a Leader in the Everest Group PEAK Matrix ® Assessment for AI-Enabled Claims Management Systems for P&C Insurance.
Article content
Everest Group's evaluation assessed multiple criteria, including providers' vision and strategy, technology capabilities, flexibility of deployment, customer engagement models, support services, and the overall value delivered to clients. Insurity's position as a Leader reflects its high technical sophistication, robust product delivery, and significant market traction in helping insurers modernize and streamline claims operations through AI. Insurity Claims stood out for its comprehensive, configurable platform and consistent growth in market adoption.
Article content
'Being named a Leader by Everest Group in AI-enabled claims management is a direct reflection of our deep commitment to delivering innovation that drives measurable results for our customers,' said Sylvester Mathis, Chief Insurance and Revenue Officer at Insurity. 'This recognition affirms that our investments in AI, automation, and user-centric design are meeting the real needs of P&C insurers. We're proud to help our customers accelerate decision-making, reduce claims leakage, and improve the policyholder experience across every touchpoint.'
Article content
Insurity Claims is an AI-powered claims solution that combines intelligent automation, intuitive workflows, and seamless integration across the insurance value chain. This enables carriers and MGAs to reduce operational friction, increase speed to resolution, and scale efficiently in a dynamic market.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
35 minutes ago
- Globe and Mail
Should You Buy Eli Lilly Stock Before June 22?
(NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release new data from studies relating to multiple GLP-1 drugs. They can give investors insights into how well the drugs are doing, and whether approvals for new drugs and indications could be forthcoming in the near future. If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should you invest in this top healthcare company before June 22? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Eli Lilly to present data on multiple drugs later this month The American Diabetes Association (ADA) is hosting its 85th Scientific Sessions event in Chicago later this month, from June 20 to 23. Eli Lilly will report on data from studies related to multiple GLP-1 drugs, including tirzepatide (already approved for weight loss and diabetes under the Zepbound and Mounjaro brands), orforglipron (its oral weight-loss medication), and retatrutide -- one of the most promising GLP-1 treatments in the company's pipeline. On June 22, Eli Lilly will also be hosting an investor event which will go over key presentations from the ADA Scientific Sessions. For investors, there will be a lot of important data to unpack from all this. Encouraging data from key drugs could help lift shares of the company, as it may give investors reason to be bullish on further drug approvals, which would lead to stronger growth prospects for Eli Lilly and greater upside for the stock. The stock has struggled this year As of the end of last week, shares of Eli Lilly were flat since the start of 2025. There hasn't been a catalyst to send the stock soaring. While it has reached highs of more than $900 this year, fears of healthcare reform and a slowdown in the economy appear to be weighing on its valuation. Plus, with the stock trading at more than 60 times its trailing earnings, there can't be any hiccups along the way for Eli Lilly. At that high of a multiple, investors are going to be demanding near perfection from the business. However, Eli Lilly has been performing well. In the trailing 12 months, it has generated revenue of more than $49 billion, and its profits on that have totaled $11.1 billion. Just a few years ago, in 2022, this was a business that was only bringing in less than $29 billion in revenue. Its profit that year was much more modest at $6.2 billion. The growth in its new GLP-1 drugs has transformed the business in a strong, positive way. And that's why strong and impressive data from the upcoming ADA event could be what gets the stock rallying again. Should you buy Eli Lilly before June 22? Eli Lilly is a strong and robust business, with some promising growth prospects on the horizon. This is a stock I firmly believe can reach a $1 trillion valuation within the next few years, given just how much growth it may achieve. And if that's the case, its upside could be more than 45% from where it is today. While its year-to-date returns look unimpressive, this is a stock that has a lot more room to rise higher. Although Eli Lilly may not be the cheapest stock to own, a premium looks justifiable when factoring in the company's recent results and future growth opportunities. Buying it before the upcoming ADA event, which may light a fire under its valuation, could be a great move for investors in the long run. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CTV News
40 minutes ago
- CTV News
Elon Musk backs off from feud with Trump, saying he regrets social media posts that ‘went too far'
U.S. President Donald Trump, right, speaks during a news conference with Elon Musk in the Oval Office of the White House, Friday, May 30, 2025, in Washington. (AP Photo/Evan Vucci]) Elon Musk stepped back from his explosive feud with U.S. President Donald Trump, writing on X that he regrets some of his posts about his onetime ally and that they went 'too far.' Early Wednesday morning, he posted 'I regret some of my posts about President @realDonaldTrump last week. They went too far.' Musk's break with a president whom he spent hundreds of millions of dollars to elect appeared to put an end to his influence in the White House and prompted concerns about effects on his companies. As a major government contractor, Musk's businesses could be particularly vulnerable to retribution, and Trump has already threatened to cut Musk's contracts. Musk earlier deleted a post in which he claimed without evidence that the government was concealing information about the president's association with infamous pedophile Jeffrey Epstein. Meanwhile, other posts that irritated Trump, including ones in which Musk called the spending bill an 'abomination' and claimed credit for Trump's election victory, remained live. On Sunday, Trump told NBC's Kristen Welker that he has no desire to repair their relationship and warned that Musk could face ' serious consequences ' if he tries to help Democrats in upcoming elections. The Associated Press
Globe and Mail
an hour ago
- Globe and Mail
Where Will Constellation Brands Stock Be in 5 Years?
Constellation Brands (NYSE: STZ), one of the world's largest producers of beer, wine, and spirits, might seem like a reliable long-term investment. But over the past five years, its stock slipped 8% as the S&P 500 advanced 86%. Why did Constellation fizzle -- and could it be a winning investment over the next five years? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » What happened over the past five years? Constellation sells more than 100 brands of alcoholic beverages. It generates most of its revenue and growth from its beer business, which includes popular labels such as Modelo, Corona, and Pacifico. Its top wine brands include Kim Crawford, Robert Mondavi, and The Prisoner; and its leading spirits include Casa Noble tequila, Svedka vodka, and High West whiskey. In its fiscal 2025 (which ended in February), Constellation generated 83.7% of its revenue from beer, 14.2% from wine, and 2.1% from spirits. That was a significant shift from fiscal 2020, when it generated 67.3% of its revenue from beer, 28.4% from wine, and 4.3% from spirits. From fiscal 2020 to fiscal 2025, revenue grew at a compound annual rate of 4%. But that growth was entirely driven by its beer business, which offset its weakening sales of wine and spirits. Business Segment Fiscal 2021 Fiscal 2022 Fiscal 2023 Fiscal 2024 Fiscal 2025 Beer revenue growth 8% 11% 11% 9% 5% Wine revenue growth (7%) (18%) (5%) (10%) (7%) Spirits revenue growth (8%) (25%) 6% (7%) (11%) Total revenue growth 3% 2% 7% 5% 2% Data source: Constellation Brands. Constellation's wine and spirits business shrank during those five years as it divested dozens lower-margin brands -- including Clos du Bois, Black Box, and Paul Masson -- in a bid to expand its faster-growing premium brands. However, the company's beer sales growth also decelerated over the past two years amid supply and capacity constraints in Mexico (which were exacerbated after local voters and Mexico's government blocked the company's plans to build a massive brewery in Mexicali), price hikes that reduced sales, and the broader weakness of the U.S. beer market -- which is struggling as today's younger consumers drink fewer alcoholic beverages than prior generations. On the bottom line, Constellation turned unprofitable on a generally accepted accounting principles (GAAP) basis in fiscal 2022 and fiscal 2023 as the value of its investment in the Canadian cannabis company Canopy Growth withered. Constellation turned profitable again in fiscal 2024, but posted another loss in fiscal 2025 as the company booked a big impairment charge from the ongoing divestments of its lower-margin wine and spirits brands. On a non-GAAP basis, its comparable EPS grew at a compound annual rate of 9% from fiscal 2020 to fiscal 2025. Constellation's near-term challenges Constellation's core business seems stable, but President Donald Trump's tariffs on imports from Mexico could severely hamper the near-term growth of its beer business, which relies heavily on the Modelo, Corona, and Pacifico brands. For fiscal 2026, management expects its organic sales to stay nearly flat -- in the range of down 2% to up 1% -- as growth of as much as 3% in beer sales offsets the double-digit percentage declines of its wine and spirit segments. It will continue to prune its wine and spirits portfolio to strengthen its higher-margin brands. But on the bottom line, Constellation expects its non-GAAP EPS to decline by 8% to 11% if the current 25% tariffs against Mexican imports (which mainly affect its canned beers) remain unchanged. It could offset some of that pressure by shipping more of its beers in glass bottles, but roughly 39% of its beer shipments from Mexico come in aluminum cans. It also can't follow Coca-Cola 's example and use more plastic bottles to dodge the tariffs, since plastic bottles affect the carbonation and taste of alcoholic beverages. Constellation could attempt to pass the costs of those tariffs on to U.S. consumers by raising its prices, but the wobbly demand for alcohol among younger and lower-income consumers could sap its pricing power. Instead, it will likely need to rely more heavily on the premiumization of its wine and spirits portfolio to weather the near-term headwinds. What will happen to Constellation over the next five years? From fiscal 2025 to fiscal 2028, analysts expect Constellation's revenue to decline from $10.2 billion to $9.9 billion as it divests itself of more brands. However, they expect it to turn profitable again on a GAAP basis in fiscal 2026 and grow its EPS at a compound annual rate of 7% over the two years that follow. Assuming Constellation's results are in line with those estimates, it continues to grow its EPS at a compound annual rate of 7% over the following three years, and that it still trades at 14 times forward earnings as of the beginning of its fiscal 2031 (in March 2030), its stock would rally by about 45% to nearly $250 over the next five years. To deliver that decent gain, Constellation will have to overcome the tariff-generated headwinds while refining its wine and spirits portfolio. But the company might still underperform other consumer staples stocks that have more irons in the fire, or the S&P 500, which has generated an average annualized return of 10% since its inception. Should you invest $1,000 in Constellation Brands right now? Before you buy stock in Constellation Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Constellation Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
